This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing Morphic's MORF-057 and the data on the endoscopic improvement in patients with ulcerative colitis recently published at the United European Gastroenterology Week Conference

Ticker(s): MORF

Who's the expert?

Institution: University of Cincinnati

  • Adjunct Professor at University of Cincinnati.
  • Research focuses on the mechanisms of cellular damage and repair processes, including epithelial barrier function disruption, intestinal pathogens and commensals, and the use of animal models.
  • His work has resulted in the development of several new drugs and diagnostic tests for the treatment of a range of gastrointestinal/liver/nutrition conditions including identification of adhesion molecules (integrins)involved in inflammatory bowel diseases in human intestinal lymphocytes and early work in phase 1-2 trials of systemic antisense oligonucleotides in intestinal inflammation. ​

Interview Goal
This discussion will focus on the open-label study data published that showed 25.7% of the 35 patients in the trial saw endoscopic improvement in comparison to the 40% of the patients in the pivotal trial for Takeda’s Entyvio

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.